Treatment of influenza A infection in children.
Diminishes replication of influenza A virus by inhibiting uncoating of the virus.
When given prophylactically, prevents infection with influenza A virus. When administered within 48 hr of onset of infections, decreases the duration of fever and other associated symptoms.
Absorption: Well absorbed after oral administration.
Metabolism and Excretion: Mostly metabolized by the liver; <25% excreted unchanged in urine.
Half-life: 25 hr (range 13–65 hr).
TIME/ACTION PROFILE (blood levels)
Use Cautiously in:
CNS: SEIZURES, agitation, dizziness, fatigue, headache, impaired concentration, insomnia, mental depression
GI: abdominal pain, anorexia, diarrhea, dry mouth, dyspepsia, nausea, vomiting
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults): Prevention- 100 mg twice daily (duration range = 11 days-6 wk). Treatment- 100 mg twice daily for 7 days.
PO (Geriatric Patients , Patients with Severe Hepatic or Severe Renal Impairment [CCr <30 mL/min]): Prevention- 100 mg daily.
PO (Children 10–16 yr): Prevention- 100 mg twice daily (duration range = 5–6 wk).
PO (Children 1–9 yr): Prevention- 5 mg/kg/day as a single dose (not to exceed 150 mg/day) (duration range = 5–6 wk).
Tablets: 100 mg
Do not administer within 48 hr before or 2 wk after administration of intranasal influenza virus vaccine ( FluMist ).
Avoidance of or reduction in symptoms associated with influenza A infection.
Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Complete Product Information.